Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 654 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant MOST POPULAR Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy July 22, 2024 The Growths On This Woman’s Lips Are A Sign That She... April 17, 2020 The Unique Challenges Teenagers and Young Adults With Cancer Face: An... January 4, 2021 Cancer Research UK announces appointment of new Chair March 28, 2023 Load more HOT NEWS What Is Pancreatic Enzyme Replacement Therapy in Cancer Care? No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... News digest – cancer blood test, gum disease and junk food... Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced...
